# US 2025/0152571 A1 · Pharmaceutical composition of antiplatelet drug, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152571 A1
- Document ID: US20250152571A1
- Status: Published application
- Kind: A1
- Application number: 18/832,936
- Filed: 2023-01-30
- Published: 2025-05-15
- Earliest claimed: 2022-01-28
- Assignees: Shanghai Curegene Pharmaceutical Co Ltd.
- Applicants: Shanghai Curegene Pharmaceutical Co., Ltd.
- Inventors: Gongxin HE; Changliang LU; Hao WU
- Web page: https://patentgrep.com/patent/US20250152571A1

## CPC

- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/4525: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/724: Cyclodextrins
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C07D 211/72: with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A pharmaceutical composition comprising a compound shown in formula (I) or a pharmaceutically acceptable salt thereof, a cyclodextrin, and optionally, a buffer. Additionally provided are a preparation method for the pharmaceutical composition and a method for using same for treating vascular diseases or inhibiting platelet aggregation.

## Claims

### Claim 1

A pharmaceutical composition, comprising:
a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and
a cyclodextrin,
wherein
represents a double bond in Z or E configuration;
R1 is selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, amino, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, and heteroalknyl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, and heteroalknyl is optionally substituted with one or more Ra;
R2 is —C(O)Rb;
R3 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalknyl, saturated or partially unsaturated cycloalkyl, saturated or partially unsaturated heterocyclyl, aryl, and heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is optionally substituted with cyano, halogen, hydroxyl, amino, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl;
L is selected from the group consisting of a direct bond, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalknyl, saturated or partially unsaturated cycloalkyl, saturated or partially unsaturated heterocyclyl, aryl, and heteraryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalknyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is optionally substituted with one or more R;
W is selected from the group consisting of:
wherein the * end of W is connected to L;
R4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalknyl, saturated or partially unsaturated cycloalkyl, saturated or partially unsaturated heterocyclyl, aryl, and heteraryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is optionally substituted with cyano, halogen, hydroxyl, amino, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl;
each of Ra is independently selected from the group consisting of hydrogen, halogen, hydroxyl, amino, cyano, nitro, or —NRcRd;
Rb is selected from the group consisting of hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalknyl, saturated or partially unsaturated cycloalkyl, saturated or partially unsaturated heterocyclyl, aryl, heteraryl, —NRcRd and —ORe;
each of Rc and Rd is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, and heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl and heteroaryl is optionally substituted with cyano, halogen, hydroxyl, or amino;
Re is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or partially unsaturated cycloalkyl, saturated or partially unsaturated heterocyclyl, aryl, and heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is optionally substituted with cyano, halogen, hydroxyl, amino, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, or heteroalkynyl;
each of Rf is independently selected from the group consisting of hydrogen, cyano, halogen, hydroxyl, amino, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or partially unsaturated cycloalkyl, saturated or partially unsaturated heterocyclyl, aryl, and heteroaryl; or
two Rf together with the atom to which they are both attached, form saturated or partially unsaturated cycloalkyl, or saturated or partially unsaturated heterocyclyl, wherein each of cycloalkyl and heterocyclyl is optionally substituted with cyano, halogen, hydroxyl, amino and alkyl;
Rg is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or partially unsaturated cycloalkyl, saturated or partially unsaturated heterocyclyl, aryl, and heteroaryl, wherein each of hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is optionally substituted with cyano, halogen, hydroxyl, or amino;
n is 0, 1, 2, 3, 4 or 5.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the cyclodextrin is β-cyclodextrin; and/or
the pharmaceutical composition is a solution; and/or
wherein the weight ratio of the cyclodextrin to the compound or the pharmaceutically acceptable salt thereof is 50:1 to 400:1, 50:1 to 300:1, 50:1 to 250:1, 60:1 to 250:1, 70:1 to 200:1, 80:1 to 150:1, or 90:1 to 120:1, wherein the weight of the pharmaceutically acceptable salt of the compound is based on the weight of the compound contained therein; and/or
wherein the pharmaceutical composition further comprises a buffer.

### Claim 3 (depends on 2)

The pharmaceutical composition according to claim 2, wherein the β-cyclodextrin is sulfobutyl ether-β-cyclodextrin, cyclobutyl alkyl ether-β-cyclodextrin, or hydroxypropyl-β-cyclodextrin.

### Claim 4

(canceled)

### Claim 5 (depends on 2)

The pharmaceutical composition according to claim 2, wherein the solution comprises 0.1-10 mg/mL, 0.2-10 mg/mL, 0.3-5 mg/mL, 0.4-2 mg/mL, 0.5-1 mg/mL, or 0.6-0.9 mg/mL of the compound or the pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 2)

The pharmaceutical composition according to claim 2 wherein the solution comprises 20-400 mg/mL, 30-300 mg/mL, 40-300 mg/mL, 50-250 mg/mL, 60-200 mg/mL, 70-150 mg/mL, or 80-100 mg/mL of the cyclodextrin.

### Claim at position 7

-8. (canceled)

### Claim 9 (depends on 2)

The pharmaceutical composition according to claim 2, wherein the buffer is an acidic buffer.

### Claim 10 (depends on 9)

The pharmaceutical composition according to claim 9, wherein the acidic buffer is selected from phosphoric acid, hydrochloric acid, succinic acid, acetic acid, tartaric acid, lactic acid, citric acid, malic acid, glycolic acid, or hydrates thereof.

### Claim 11 (depends on 9)

The pharmaceutical composition according to claim 9, wherein the acidic buffer is citric acid monohydrate.

### Claim 12 (depends on 11)

The pharmaceutical composition according to claim 11, wherein the solution comprises 1-3 mg/mL, 1-2.5 mg/mL, or 1-2 mg/mL of citric acid monohydrate.

### Claim 13 (depends on 2)

The pharmaceutical composition according to claim 2, wherein the pharmaceutical composition has a pH of 3-4.

### Claim 14 (depends on 2)

The pharmaceutical composition according to claim 2, wherein the pharmaceutical composition is a lyophilized composition formed by lyophilization of the solution.

### Claim at position 14

-45. (canceled)

### Claim 46 (depends on 1)

The pharmaceutical composition according to claim 1, having a formula selected from the group consisting of:

### Claim at position 16

-48. (canceled)

### Claim 49 (depends on 1)

The pharmaceutical composition according to claim 1, wherein is a double bond in Z configuration, and/or R1 is halogen and n is 1.

### Claim at position 18

-51. (canceled)

### Claim 52 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the compound has a formula selected from the group consisting of:

### Claim 53 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the compound is:

### Claim at position 21

-58. (canceled)
